Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
IPO Year: 2012
Exchange: NASDAQ
Website: atossatherapeutics.com
DEF 14A - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
S-8 - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
10-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
8-K - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
424B5 - ATOSSA THERAPEUTICS, INC. (0001488039) (Filer)
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-
SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes that pursuing a metastatic indication may offer a more efficient regulatory pathway to deliver (Z)-endoxifen to women in urgent need, and simultaneously plans to work with the FDA to advance additional indications, such as breast cancer prevention and neoadjuvant therapy, that often require larger and longer clinical trials. Addressing the High Unmet Need
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, extends its sincere congratulations to Dr. Tessa Cigler, esteemed Board Director at Atossa and Associate Professor of Clinical Medicine at Weill Cornell Medicine, and the Weill Cornell Medicine team for being awarded a five-year, $2.3 million grant from the Centers for Disease Control and Prevention (CDC). This grant will fund initiatives aimed at improving equitable access to care, quality of life, and survival outcomes for young breast cancer patients across New York City. Dr
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board's (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the "'334 patent"). Atossa is disappointed with the PTAB's decision finding all challenged claims in the '334 patent unpatentable and is evaluating its options. This decision has no impact on the formulations currently in clinical development by Atossa. While Atossa disagrees with the decision and believes t
SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company's clinical programs and recent events. The full text of the letter follows: To our valued shareholders, As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment. Last year was vital for Atossa as we c
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, commends the U.S. Surgeon General for issuing a crucial Advisory that describes the scientific evidence for the causal link between alcohol consumption and increased cancer risk, particularly breast cancer in women. The Surgeon General's Advisory reveals that alcohol consumption contributes to nearly 100,000 cancer cases and approximately 20,000 cancer deaths in the United States each year – making it the third leading preventable cause of cancer, after tobacco and obesity. Not
SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced data describing the discovery of compounds that may be synergistic with (Z)-endoxifen and that could potentially be used in combinations for the treatment of breast cancer. The data is being presented in a poster at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. The poster, titled, "Discovery of molecules synergistic with (Z)-endoxifen for the treatment of breast ca
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium SEATTLE, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced full results from its Phase 2 KARISMA-Endoxifen trial conducted at the Karolinska Institute in Stockholm, Sweden. The data, which will be presented during a Poster Spotlight Session at the 2024 San Antonio Breast Cancer Symposium, highlight the potential of low-dose (Z)-endoxifen to significantly reduce mammographic brea
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that three posters involving pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS 2024). EVANGELINE is a randomized Phase 2 non-inferiority study investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with estrogen receptor-positive (ER+)/HER2-negative breast cancer. The first poster, "N
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
SC 13G/A - ATOSSA THERAPEUTICS, INC. (0001488039) (Subject)
Ended 2024 with $71.1 million of cash and cash equivalents and no debt Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments. Fourth Quarter and Early 2025 Highlights Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic bre
SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Company will host a conference call and live audio webcast on Tuesday, March 25, 2025, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2024. The webcast will be available at the investor relations section of the Company's website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-
SEATTLE, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines to address significant unmet needs in cancer, today announced that it will provide a business update and report financial results for the second quarter 2023 on Monday, August 14, 2023. Company management will host a conference call to review the results at 9:00 a.m. ET / 6:00 a.m. PT on August 14, 2023. Second Quarter 2023 Conference Call DetailsDate: Monday, August 14, 2023Time: 9:00 a.m. ET / 6:00 a.m. PTParticipant Registration: https://edge.media-server.com/mmc/p/2qtrmqz3 Interested participants should register for the confere
Two Phase 2 trials investigating (Z)-endoxifen in neoadjuvant setting initiated and are enrolling patientsFull enrollment of Phase 2 KARISMA mammographic breast density study expected by end of 2023Ended first quarter 2023 with $103.9 million of cash and cash equivalents and no debt SEATTLE, May 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company developments. Key de
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date include: Received FDA authorization from FDA to initiate its Phase 2 study of neoadjuvant (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer. Invested in a privately-held Dynamic Cell T
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments. Key developments from Q2 2022 and to date include: Completed dosing in both Part B and Part C (of four parts) of Phase 1/2a Clinical Trial of AT-H201 in healthy volunteers, which the Company was developing as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2022, and provides an update on recent company developments. Key developments from Q1 2022 and to date include: Received issuance of key U.S. patent covering Endoxifen directed to compositions of storage-stable Endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable Endoxifen.Announced planned U.S. Phase 2 clinical stu
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter and fiscal year ended December 31, 2021 and provides an update on recent company developments. Key developments from Q4 2021 and to date include: Initiated enrollment of our Phase 2 clinical study of proprietary oral Z-endoxifen (or "Endoxifen") in Sweden. Participants in the study will be premenopausal women with measurable mammographic breast density.Completed a pre-investigation
SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended September 30, 2021, and provides an update on recent company developments. Key developments from Q3 2021 and to date include: Began to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for "long-haul" pat
SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2021, and provides an update on recent company developments. Key developments from Q2 2021 and to date include: Atossa received final data from its open-label Phase 2 clinical study of oral Endoxifen administered in the "window of opportunity" between diagnosis of breast cancer and surgery, which showed that the primary endpoint of the study was achieved:
Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factorReleased a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatmentAnnounced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO)Received a new patent (U.S. Patent No. 12
SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Claudia Lopez, DVM, MSc, as its new Vice President, Clinical Product Development. Dr. Lopez brings more than two decades of clinical development and strategic expertise to Atossa, including leadership roles in global clinical programs across immunology, oncology, and metabolic disease. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. Dr. Lopez most recently served as Vice President of Clinical Development at Landos Biopharma, where she oversaw global clinical strategies, trial
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "We are excited to welcome Michael t
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced the appointment of Heather Rees as the Company's new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa's Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Ms. Rees brings almost 30-years of accounting, business and financial experience to the CFO role. She has spent the last seven years of her career at Atossa having joined the Company as Controller in 2017.
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. "Atossa's inclusion in the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company," said St
SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Tessa Cigler, M.D., M.P.H. was appointed to Atossa's board of directors, effective immediately. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City. "We are pleased to welcome Dr. Cigler to our board of directors," said Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer. "Tessa works daily with breast cancer patients
SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad as Senior Medical Director. "We are excited to welcome Dr. Mirad to Atossa and look forward to leveraging her extensive experience in the clinical development of oncology candidates to further accelerate our (Z)-endoxifen development program," said Dr. Steven Quay, CEO and Chairman of Atossa Therapeutics. "With four ongoing Phase 2 trials in three distinct settings, several years of working capita
SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Jonathan Finn, CFA, has been appointed to Atossa's board of directors, effective November 8, 2023. Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology companies. Mr. Finn currently serves as Executive Vice President and Chief Investment Officer at Vantage Consulting Group, an investment advisory firm. In this role, he directs investment strategy, asse
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)
4 - ATOSSA THERAPEUTICS, INC. (0001488039) (Issuer)